News | June 24, 2011

American Heart Association CEO Praises Graphic Tobacco Warning Labels

June 24, 2011 — American Heart Association (AHA) CEO Nancy Brown praised the new, larger tobacco packaging warning labels unveiled this week by the U.S. Food and Drug Administration (FDA). The labels include graphic images of disease caused by tobacco.

“New cigarette warning labels unveiled today by the Food and Drug Administration will help give us the momentum needed to eradicate tobacco use in our nation,” Brown said. “For the first time in 25 years, cigarette warning labels have been dramatically altered to graphically demonstrate the specific, serious health risks associated with smoking, and these warnings will not only tell smokers how bad tobacco use is, but also direct them to smoking cessation resources that can help them quit.”

According to the Centers for Disease Control and Prevention, more than 45 million Americans smoke cigarettes - about 20 percent of the population - and one in five high school students still smoke. The new health warnings represent an aggressive approach to reducing smoking rates that have leveled off in recent years as tobacco companies continue to launch campaigns to entice new smokers and maintain current customers.

“The American Heart Association strongly believes that the graphic depictions of smoking-related diseases on cigarette packages will drive home the message that tobacco use is an equal opportunity killer, affecting smokers and nonsmokers alike,” Brown said. “In the U.S., about one-third of smoking-related deaths are linked to heart disease and stroke. Cigarette smoking causes about 443,000 premature deaths each year and about 49,000 of these deaths are due to second-hand smoke. Undoubtedly, the new graphic health warnings will heighten awareness about the dangers of smoking and, more importantly, encourage smokers to quit and discourage smoking initiation. We're confident that the new labels will move us closer to our goal of making the nation 100 percent smoke-free.”

For more information: www.heart.org


Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init